Phase 2 study with Baker's antifol in solid tumors

V. Rodriguez, Stephen P Richman, R. S. Benjamin, M. A. Burgess, W. K. Murphy, M. Valdivieso, R. L. Banner, J. U. Gutterman, G. P. Bodey, E. J. Freireich

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.

Original languageEnglish
Pages (from-to)980-983
Number of pages4
JournalCancer Research
Volume37
Issue number4
StatePublished - Dec 1 1977
Externally publishedYes

Fingerprint

triazinate
Dermatitis
Neoplasms
Stomatitis
Renal Cell Carcinoma
Sarcoma
Colorectal Neoplasms
Melanoma
Appointments and Schedules
Adenocarcinoma
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rodriguez, V., Richman, S. P., Benjamin, R. S., Burgess, M. A., Murphy, W. K., Valdivieso, M., ... Freireich, E. J. (1977). Phase 2 study with Baker's antifol in solid tumors. Cancer Research, 37(4), 980-983.

Phase 2 study with Baker's antifol in solid tumors. / Rodriguez, V.; Richman, Stephen P; Benjamin, R. S.; Burgess, M. A.; Murphy, W. K.; Valdivieso, M.; Banner, R. L.; Gutterman, J. U.; Bodey, G. P.; Freireich, E. J.

In: Cancer Research, Vol. 37, No. 4, 01.12.1977, p. 980-983.

Research output: Contribution to journalArticle

Rodriguez, V, Richman, SP, Benjamin, RS, Burgess, MA, Murphy, WK, Valdivieso, M, Banner, RL, Gutterman, JU, Bodey, GP & Freireich, EJ 1977, 'Phase 2 study with Baker's antifol in solid tumors', Cancer Research, vol. 37, no. 4, pp. 980-983.
Rodriguez V, Richman SP, Benjamin RS, Burgess MA, Murphy WK, Valdivieso M et al. Phase 2 study with Baker's antifol in solid tumors. Cancer Research. 1977 Dec 1;37(4):980-983.
Rodriguez, V. ; Richman, Stephen P ; Benjamin, R. S. ; Burgess, M. A. ; Murphy, W. K. ; Valdivieso, M. ; Banner, R. L. ; Gutterman, J. U. ; Bodey, G. P. ; Freireich, E. J. / Phase 2 study with Baker's antifol in solid tumors. In: Cancer Research. 1977 ; Vol. 37, No. 4. pp. 980-983.
@article{f0f0534fdf4e4c04bd2b7607d5921349,
title = "Phase 2 study with Baker's antifol in solid tumors",
abstract = "One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10{\%}. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13{\%}), in 25 patients with colorectal carcinoma (partial response, 16{\%}), and in 6 patients with renal cell carcinoma (partial response, 50{\%}). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.",
author = "V. Rodriguez and Richman, {Stephen P} and Benjamin, {R. S.} and Burgess, {M. A.} and Murphy, {W. K.} and M. Valdivieso and Banner, {R. L.} and Gutterman, {J. U.} and Bodey, {G. P.} and Freireich, {E. J.}",
year = "1977",
month = "12",
day = "1",
language = "English",
volume = "37",
pages = "980--983",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Phase 2 study with Baker's antifol in solid tumors

AU - Rodriguez, V.

AU - Richman, Stephen P

AU - Benjamin, R. S.

AU - Burgess, M. A.

AU - Murphy, W. K.

AU - Valdivieso, M.

AU - Banner, R. L.

AU - Gutterman, J. U.

AU - Bodey, G. P.

AU - Freireich, E. J.

PY - 1977/12/1

Y1 - 1977/12/1

N2 - One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.

AB - One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.

UR - http://www.scopus.com/inward/record.url?scp=0017582645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017582645&partnerID=8YFLogxK

M3 - Article

C2 - 139205

AN - SCOPUS:0017582645

VL - 37

SP - 980

EP - 983

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 4

ER -